Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04793711 · ClinicalTrials.gov registry record · NA
EpiCeram for Skin Protection in Healthcare Workers
A NA study, sponsored by Primus Pharmaceuticals.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04793711 is a NA study that was terminated before completion, run by Primus Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT04793711, a NA study, was terminated before completion, sponsored by Primus Pharmaceuticals.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label study using a device currently prescribed by doctors. This means everyone involved in the study will know the name of the product, only one product will be used, and the U.S. Food and Drug Administration (FDA) has approved the sale of this product. Although this is called a device, the product is an emollient-type lotion. Healthcare workers (HCW) often suffer from signs and symptoms of skin irritation, including pain, redness, roughness, dryness, cracking and itching due to the extensive use of personal protective equipment (PPE) such as masks and gloves. These are thought to be due to changes in the normal skin barrier function induced by repeated minor abrasion in the warm, moist environment induced by extensive use of PPE required at work. EpiCeram Controlled Skin Barrier Emulsion (EpiCeram) is a prescription skin barrier repair product containing ingredients designed to improve skin barrier function. However, EpiCeram has not previously been studied in people with skin irritation due to extensive use of PPE. This study was terminated after 1 (one) subject was enrolled due to the inability to find willing participants.
Interventions
- DEVICE EpiCeram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2021-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04793711
The ClinicalTrials.gov registry entry for NCT04793711 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EpiCeram is the first listed.
NCT04793711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04793711 about?
NCT04793711 is a clinical study titled "EpiCeram for Skin Protection in Healthcare Workers". This is an open-label study using a device currently prescribed by doctors. This means everyone involved in the study will know the name of the product, only one product will be used, and the U.S. Food and Drug Administration (FDA) has approved the sale of this product. Although this is called a dev...
What is the current status of trial NCT04793711?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2021-03-15. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT04793711?
The interventions under investigation include: EpiCeram (DEVICE).
Who is sponsoring clinical trial NCT04793711?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.